Rani Therapeutics (NASDAQ: RANI) is trading higher this morning after the company announced that the FDA accepted its RaniPill platform into its Emerging Technology Program. This gives Rani earlier and more direct access to FDA officials as it works through manufacturing and regulatory issues associated with the technology.

‍

The Rani pill

‍

A lot of biologic drugs have to be injected because they're too large and fragile to survive the digestive system and reach the bloodstream effectively. Rani wants to put those drugs into a pill.

‍

You see, RaniPill is swallowed like a normal capsule. But once it reaches the small intestine, the capsule is designed to deliver the drug through the intestinal wall, allowing medicines that would normally require an injection or IV infusion to potentially be taken orally instead.

‍

The FDA's Emerging Technology Program doesn't mean the agency has approved RaniPill or any drug using it. What it does mean is that Rani can work directly with the FDA's Emerging Technology Team on questions surrounding the platform, including manufacturing, regulatory requirements, and potentially the technology's use across multiple drugs.

‍

That's particularly useful because Rani isn't building RaniPill around a single treatment.

‍

The company has partnerships spanning rare diseases, immunology, and obesity, including collaborations with Chugai, ProGen, and PegBio.

‍

The obesity angle

‍

Rani is developing RT-114 with ProGen, using RaniPill to orally deliver PG-102, a GLP-1/GLP-2 drug candidate. Initial Phase 1a results showed oral delivery produced systemic drug exposure exceeding 150% of matched subcutaneous dosing. Rani has since expanded that study and expects additional data by the end of 2026, with a Phase 1b obesity study planned afterward.

‍

In other words, there's already some early human evidence showing the delivery system can get a large biologic drug into the bloodstream.

‍

For a company with a market cap around $100 million, this is not trivial.  So keep this one on your radar. 

‍